Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study-Reference-Cited by-同舟云学术

Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study

Published:2017-10-18 Issue:2 Volume:21 Page:192-200
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Skinner Karen E.¹,Fernandes Ancilla W.²,Walker Mark S.¹,Pavilack Melissa²,VanderWalde Ari³

Affiliation:

1. Vector Oncology, Memphis, TN, USA;

2. AstraZeneca, Gaithersburg, MD, USA;

3. West Cancer Center, Memphis, TN, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2017.1389744

Reference31 articles.

1. Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung

2. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer statistics review, 1975–2014. Bethesda, MD: National Cancer Institute. Available at: https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site

3. National Cancer Institute (NIH). Financial burden of cancer care. NIH; 2017. Available at: https://progressreportcancergov/after/economic_burden

4. National Comprehensive Cancer Network (NCCN). NCCN guidelines version 6.2107: non-small cell lung cancer. NCCN; 2017. Available at: https://nccn.org/

5. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost of early progression: patients with epidermal growth factor receptor mutated metastatic non-small-cell lung cancer;Future Oncology;2024-07-16

2. Real-world clinical and economic outcomes for patients with advanced non–small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy;Journal of Managed Care & Specialty Pharmacy;2024-07

3. Traitement ciblé oral contre le cancer du poumon non à petites cellules;Canadian Medical Association Journal;2024-06-09

4. Healthcare Resource Utilization and Associated Costs among Patients with Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy or Immunotherapy in Spain: A Single-Center, Real-World, Exploratory Study;Cancers;2024-05-30

5. Oral targeted therapy for the treatment of non–small cell lung carcinoma;Canadian Medical Association Journal;2024-04-28